Pharmgate Animal Health appoints key management team.

May 5, 2010 — Pharmgate Animal Health is pleased to announce the appointments of Peter Criddle as Vice President of Finance & Operations (and interim General Manager) and Edward Seed as Vice President of Sales & Marketing. Together, Peter and Ed bring in excess of 40 years experience and a history of successful innovation and operations in the animal health industry. This experience, together with our value proposition which combines innovative therapeutic options with an optimized supply chain, will establish Pharmgate Animal Health as the dynamic new player in the animal health marketplace.

Peter began his career in finance within the animal feed industry in the UK. In 1995 he moved to North America as part of the global animal health business of Roche. Transitioning into supply chain and operations management, Peter became Senior Vice President of Global Operations for Alpharma Animal Health. After a number of years in another industry, Peter is very pleased to be back, driving supply chain excellence and creating value for the animal health industry.

Ed has more than 20 years product development, marketing and regional management experience in leading animal nutrition and health companies including Elanco, Roche and Alpharma. This has included sales and marketing management positions in Europe and North America, and more recently the position of global swine business unit leader. He holds an MS in Animal Nutrition and a post-graduate Marketing Management diploma.

About Pharmgate Animal Health

Pharmgate Animal Health LLC is the recently formed joint venture between Pharmgate LLC, the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., the world leader in the production of chlortetracycline feed grade, chlortetracycline hydrochloride, salinomycin and ECO Animal Health, London U.K., a leader in the development, registration and marketing of pharmaceutical products for global animal health markets including the novel macrolide antibiotic, Aivlosin™, as well as a range of generic therapeutic products.